Promising osimertinib results presented at ELCC

Two studies presented at this year’s European Lung Cancer Conference in Geneva, Switzerland, focus on the third-generation tyrosine kinase inhibitor osimertinib in patients with advanced EGFR-mutated non-small-cell lung cancer.
Source: MedWire News - Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news